CI & Patent News 12/01/2011


1) Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab “…. But Novartis’s decision will see highly unusual direct competition between the two Swiss pharmaceutical groups, which are among the world’s leaders by sales….” (FT)

2) Vertex maintains 2010 outlook, reveals launch plan for hep C drug telaprevir and progress of other programs (thepharmaletter). Shasun would supply Telaprevir API to Vertex. Telaprevir is patented in india. (212710/242/KOLNP/2003)

3) Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide (Press release).  “…. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as Lilly’s two basal insulin analogues—LY2605541 and LY2963016 as well as the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody….”

4) Interesting article on Patent term extension in Australia and case law (Patent Baristas)

5) Biocon’s oral insulin fails experiment

6) US complaint filing

(i) Pfizer vs Novel Laboratories (Pregabalin; Lyrica); patent in suits: 6,197,819; 5,563,175 & 6,001,876; View on PriorSmart

(ii) Apotex vs Forest Laboratories (escitalopram); patents in suit: 6,916,941 & 7,420,069; View on PriorSmart

7) Indian patent office decisions:

(i) 1995/DEL/2006 assigned to Les servier which is equivalent to WO2007028905 and titled “Use of agomelatine in order to obtain medicaments which are intended for the treatment of sleep disorders among depressed patients” is rejected by IPO on 3(d) and 3(e). Decision

(ii) 925/CHE/2003 assigned to Novartis which is divisional of IN202379 (IN/PCT/2001/783/CHE) and equivalent to WO2000033878. This application is refused on insufficiency and prior claiming Decision

(iii) 1873/CHENP/2007 assigned to Shin poong pharma which is equivalent to WO2006049391. This invention is pertaining to combination of two anti malarial drug. The controller stated that synergestic therapeutic effect requirement under section 3(d) and 3(e) is demonstrated, but refused to grant because lack inventive step. Decision

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news, Patent case. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s